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ABSTRACT 
Purpose: Altered fractionation radiotherapy with concomitant boost (AFRT-CB) may be considered an 
alternative treatment for patients not appropriate for chemoradiation (CRT). As functional outcomes 
following AFRT-CB have been minimally reported, this exploratory paper describes the outcomes of 
patients managed with AFRT-CB or CRT at 6 months post treatment.  
Methods: Using a cross-sectional analysis design, functional outcomes of 14 AFRT-CB and 17 CRT 
patients with T1-T3 oropharyngeal cancers were explored at 6 months post-treatment. Clinical and 
instrumental swallow assessments, weight and nutritional status, and the functional impact of treatment 
were examined.  
Results: Inferior outcomes were observed for the CRT patients on the RBHOMS (p = 0.03) which was 
reflected in diet and fluid restrictions with 18% of the CRT group requiring modified fluids and diets. 
Although a trend (p = 0.07) was noted for increased lingual deficits and aspiration risk for fluids in the 
CRT group, no other significant differences were observed. Both groups experienced an average of 
10kg weight loss and reported reduced general and swallowing related function. 
Conclusions: This preliminary data suggests functional outcomes following AFRT-CB and CRT were 
largely comparable at 6 months post treatment. Treatment intensification in any form may contribute to 
impaired function which requires multidimensional intervention. Larger cohort investigations with 
systematic methodology are needed to further examine these initial findings.  
 
Keywords: swallowing, nutrition, oropharyngeal cancer, chemoradiation, altered fractionation 
radiotherapy 
This paper aims to inform research by providing further evidence for functional outcomes following 
non-surgical treatment for head and neck cancer. 
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INTRODUCTION 
The past two decades have revealed a trend for individuals with oropharyngeal cancer to receive non-
surgical organ preservation treatment such as altered fractionation radiotherapy (AFRT) or 
chemoradiation (CRT). While evidence to date has pointed to increased acute toxicity following these 
more intense treatment regimens when compared with conventional radiotherapy [1-4], exactly how 
the outcomes for swallowing, nutrition and patient-perceived deficits vary between such intensive 
treatment modes is still being elucidated [5, 6]. In particular, the majority of research to date has 
examined outcomes following CRT, with limited detail on AFRT and how the two treatment 
modalities compare. 
 
AFRT techniques have been found to improve locoregional control and survival in locally advanced 
head and neck squamous cell carcinoma (LAHNSCC) patients, but can result in more intense acute 
toxicity, which may last longer when compared with conventionally fractionated radiotherapy [2, 7], 
result in consequential late reactions [8, 9] and possible long-term functional injury [2]. Altered 
fractionation with concomitant boost (AFRT-CB) has been found to lead to significantly increased late 
effects (grade 3 or worse on the RTOG radiation morbidity scoring criteria) when compared with 
standard fractionation, hyperfractionation or accelerated fractionation with a split, although no 
difference was found by 6 months post-treatment [2]. In support of these findings, a retrospective study 
using a crude measure of dysphagia found AFRT and its acute toxicity affected swallowing function 
with resolution by 12 months post-treatment for most patients [6]. In addition the current evidence base 
for nutritional outcomes and patient-rated function following AFRT is also limited. 
 
In comparison, documentation of swallowing and nutrition outcomes following CRT regimens is more 
prevalent. Although improving locoregional control and overall survival in [10], toxicity related to 
concurrent CRT regimens has been found to be significantly higher when compared to standard 
radiotherapy [1, 11], and severe late swallowing complications have been found in 30-50% of patients 
treated with aggressive CRT regimens [4, 11]. Reported dysphagia symptoms in HNC patients who 
received chemoradiotherapy regimens are diverse and have affected the oral phase [12-14], pharyngeal 
and upper esophageal phases of swallowing [12, 13, 15, 16].  The impact on nutritional outcomes has 
been reported [5, 12, 15, 17-19], with several studies finding weight loss and nutritional compromise 
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during and following radiotherapy and CRT protocols [20, 21]. Both deleterious swallowing and 
nutritional outcomes following CRT have also been associated with poor patient-rated function [12, 15, 
17, 18]. 
 
Despite minimal reported data proving no difference in outcomes following AFRT-CB and CRT [22], 
clinical perception is that the side effects and impact on function associated with the addition of 
chemotherapy to radiation protocols are worse than for treatment with radiotherapy alone. 
Subsequently, resources for the management of patients receiving treatment for oropharyngeal cancer 
in many clinical settings are biased toward those receiving CRT. Until this time, an exploration of 
patients treated with the intent to cure, with specific tumor size and location has not been undertaken to 
prove or disprove this clinical perception.  Therefore, the current preliminary study aims to explore the 
functional outcomes (swallowing and nutrition), and patient-rated functional impact of curative intent 
AFRT-CB and CRT at 6 months post-treatment in concurrently recruited cohorts of patients with T1-
T3 oropharyngeal SCC.  
 
MATERIALS AND METHODS 
Eligibility 
This cross-sectional study recruited eligible participants from consecutive presentations to a 
Multidisciplinary Head and Neck Cancer Clinic at a large tertiary hospital in Brisbane, Australia, over 
a 33 month accrual period (between November 2006 and August 2009). Patients with T1, T2, or T3 
SCC of the oropharynx (tonsil, base of tongue [BOT]), pharyngeal wall, or supraglottis [within 1cm of 
the oropharynx]) who were recommended for treatment with CRT or AFRT-CB were targeted for 
recruitment. Decisions regarding the preferred treatment for each patient were reached by consensus 
and were the responsibility of senior physicians and surgeons. Ineligible patients included those with a 
previous diagnosis of oropharyngeal LAHNSCC, neurological or neurodegenerative condition which 
may have impacted on swallowing function. All patients received their treatment at the Metro South 
Radiation Oncology Service in Brisbane, Australia. This research was approved by the Human 
Research and Ethics Committees at the Princess Alexandra Hospital, Australia and the University of 
Queensland, and all participants consented to involvement in the study.  
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AFRT-CB was the recommended treatment for 17 patients, all of whom were eligible for recruitment. 
Two patients declined to participate, leaving a cohort of 15 participants who consented to involvement. 
Of these participants, 14 completed all aspects of the study with one participant’s data set incomplete 
as a result of death unrelated to cancer. A second group of 23 patients who received CRT were 
matched for tumor size and location, and were approached 6 months post-treatment for recruitment into 
the CRT group. Twenty participants consented to involvement in the study. Of these participants, 17 
completed all aspects of the study, with three participants’ data set incomplete due to errors in 
recording of modified barium swallow assessments or incomplete data. Analysis was conducted on the 
31 participants with complete data sets. 
 
Participants in both groups were predominantly male (AFRT-CB: 12 male, 2 female; CRT: 15 male, 2 
female), with the CRT group significantly younger than the AFRT-CB group (Table 1). Although not 
statistically different, a large proportion of AFRT-CB patients had stage I and II disease, a group which 
was not represented in the CRT group. This is likely due to the incidence and severity of nodal disease 
in CRT patients, and often a reason for prescribing CRT as the treatment of choice. For all other 
demographic variables (sex, tumor site or size, nodal disease, or alcohol and smoking history, 
dysphagia for solids/liquids at presentation), both the AFRT-CB and CRT groups were similar.  
(insert table 1 near here) 
Planned Treatment 
All patients were treated with 3D conformal RT. Patients were treated with either AFRT-CB or 
conventionally fractionated radiotherapy with or without systemic therapy. Patients with lower volume 
disease (eg. T1-2, N1) were generally considered for single modality radiotherapy. Elective sites were 
treated to 50Gy in 2Gy/day over 5 weeks. Known sites of disease received either a concomitant boost 
schedule to a total of 66Gy over 5 weeks with an afternoon boost dose (minimum of 6 hours apart) of 
1.6Gy/day in weeks 4 and 5 or 2Gy/fraction to a total of 70Gy over 7 weeks. Planned concurrent 
systemic therapy consisted of either high-dose cisplatin (100mg/m2) in weeks 1, 4 and 7 or fractionated 
weekly cisplatin (40mg/m2). Patients with contraindications to cisplatin, such as renal/hearing 
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impairment or pre-existing neuropathy, received either carboplatin/5-fluorouracil or cetuximab. 
Selection of systemic therapy was at the discretion of the treating physician. 
 
Outcome Measures 
As the aim of this study was to outline functional outcomes at 6 months post-treatment, baseline data 
was not routinely collected. Pre-treatment diet and fluid tolerance and weight recordings were collected 
retrospectively from speech pathology and dietitian medical chart entries at the initial Multidisciplinary 
Head and Neck Cancer Clinic appointment. 
 
At 6 months post-treatment, all participants underwent a range of assessments relating to swallowing, 
nutrition and the functional impact of treatment which have been described in detail elsewhere [23]. 
Swallowing was assessed both clinically and objectively. Clinical assessment included trials of diet 
(full, soft, minced, pureed) and fluid (extremely thick, moderately thick, mildly thick, or thin) 
consistencies in line with Australian national standards [24], with function scored with the Royal 
Brisbane Hospital Outcome Measure for Swallowing (RBHOMS, [25]). Objectively, swallowing was 
assessed with videofluoroscopy (VFS) and analysed with Subscale One (oral, oropharyngeal transit, 
pharyngeal and crico-esophageal parameters) of the New Zealand Index for Multidisciplinary 
Evaluation of Swallowing NZIMES [26]. Penetration and aspiration events were rated using the 
validated Penetration-Aspiration Scale [27]. Both scales were rated by a speech pathologist blinded to 
group, with greater than 5 years clinical experience in head and neck oncology.  
 
Nutritional status at 6 months post-treatment was assessed by a dietitian using the Patient-Generated 
Subjective Global Assessment (PG-SGA, [28]). Weight was recorded pretreatment and at 6 months 
post-treatment. Requirements for alternative or supplemental feeding were also noted. Patient-rated 
functional impact was assessed using the M.D. Anderson Dysphagia Inventory (MDADI, [29]) and the 
Functional Assessment of Cancer Therapy Additional Concerns for Head and Neck version 4 (FACT-
H&N, [30]). 
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Statistical Analysis 
Sample size accrual was targeted to 30 participants in each of the AFRT-CB and CRT groups, but 
could not be achieved after a collection period of 33 months. The authors acknowledge that due to the 
small participant numbers, statistical analyses are underpowered, limiting the ability to make definitive 
statements. However in recognition of the small group numbers, nonparametric statistics (Chi square, 
Mann-Whitney U) were used for all comparisons and significance was set at p < 0.05, with values 
falling between > 0.05 and <0.08 considered as trends. All statistical analysis was conducted using 
STATA version 10 for Mac. 
 
RESULTS 
Functional swallowing outcomes were found to be inferior for the CRT group, with significant 
differences noted in the RBHOMS score (AFRT-CB M = 7.57, SD = 0.85; CRT M = 6.89, SD = 1.02, 
Z = -2.14, p = 0.03). This finding was also reflected in the diet and fluid consistencies tolerated at this 
time point (Table 2). While the majority of participants from both groups were managing thin fluids 
and a full or soft diet, there were a small number of CRT participants requiring thickened fluids and a 
texture-modified diet.  
(insert table 2 near here) 
Measures of physiological swallow impairment, as scored by the NZIMES, revealed no significant 
differences between the AFRT-CB and CRT groups in the small sample studied (Table 3). A trend (p = 
0.07) was observed for more severe lingual impairment in the CRT group. Penetration and aspiration 
events, scored using the Penetration-Aspiration Scale, did not differ significantly between AFRT-CB 
and CRT groups (Table 3), although a trend for more severe penetration/aspiration on fluids in the 
CRT group (p = 0.07) was observed.  
(insert table 3 near here) 
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To further explore the data and aid descriptive interpretation of the patterns of physiological 
impairment in the two groups, the NZIMES ratings were compressed into a binary scale of 
“impairment” (score of >0) versus “no impairment” (score of 0) to reveal the frequency of specific 
impairments (Table 4). Impairment in mastication, pharyngeal contraction/bolus propulsion, laryngeal 
excursion, bolus propulsion through the UES and clearance of pyriform sinus residue was found in 
50% or more of all participants irrespective of treatment received. Additional impairments in palatal 
closure and position of the bolus at the onset of the swallow were evident in more than 30% of all 
participants. Similarly, for descriptive analysis the PAS ratings were reclassified into three broad 
categories of “nil penetration or aspiration”, “penetration”, and “aspiration” (Table 5). Almost 90% of 
the AFRT-CB did not have any penetration or aspiration or fluids compared with 53% of CRT patients. 
Patterns revealed a three-fold increase in penetration and aspiration frequency on fluids in the CRT 
group (47%) when compared with AFRT-CB patients (14%), although more than 40% of the AFRT-
CB group also had penetration/aspiration of solids.  
(insert table 4 and 5 near here) 
Nutrition outcomes for weight (AFRT-CB M = 71.42kg, SD = 17.61; CRT M = 71.71kg, SD = 19.19; Z 
= 0.04, p = 0.97) did not reveal any significant differences between the AFRT-CB and CRT groups at 6 
months post-treatment. Both groups experienced an average 10kg weight loss to 6 months post-
treatment compared with pretreatment weight. No significant difference was found for the PG-SGA 
global rating (AFRT-CB A = 79%, B = 21%; CRT A = 82%, B = 18%; χ2 = 0.07, p = 0.79) or the PG-
SGA numerical score (AFRT-CB M = 4.79, SD = 3.79; CRT M = 5.26, SD = 5.37; Z = 0.12, p = 0.9). 
At 6 months post-treatment, supplemental tube feeding was required for 12% of the CRT group (2 
gastrostomy tubes), while none of the AFRT group continued to need supplemental tube feeding. 
 
Analysis of patient-rated functional impact as scored by the FACT-H&N and MDADI revealed no 
significant differences between patients receiving AFRT-CB and CRT at 6 months post-treatment 
(Table 6). The overall FACT-H&N score revealed a pattern of greater patient-rated dysfunction for 
CRT, similar to the patient-rated global, emotional, functional and physical swallowing scores on the 
MDADI, although this sis not reach significance.  
  
 
- 9 - 
(insert table 6 near here) 
 
DISCUSSION 
This exploratory analysis suggests that treatment intensification with the addition of chemotherapy to 
conventional radiotherapy for patients with T1-T3 oropharyngeal SCC resulted in significant negative 
outcomes for functional swallowing at 6 months post-treatment compared with patients treated with 
AFRT-CB. Although preliminary in nature, these results affirm clinical perceptions that swallowing is 
worse for those who receive CRT. Despite this finding, all other parameters were not significantly 
different between the groups, with physiological swallow impairment, nutritional status and patient-
rated functional impact found to be largely comparable between the AFRT-CB and CRT patients. The 
study results have been limited by small sample size however it may be hypothesized that patients who 
receive AFRT experience long term negative swallowing and nutritional outcomes, and that the nature 
and severity of the impairments are not dissimilar to those experienced by patients undergoing CRT. 
  
With respect to the food and fluid diets managed by patients at 6 months, inferior functional 
swallowing was observed in the CRT patient group compared with those who received AFRT-CB. In 
the CRT group a small proportion still required modified fluids at 6 months, however over 80% had not 
returned to managing a normal diet, with most managing soft foods. Two CRT patients still had a 
gastrostomy tube insitu although were managing some oral intake. In comparison the AFRT-CB group 
were all managing thin fluids at the time of assessment and just under half had returned to a normal 
diet. These results are similar to those previously reported where the majority of patients resumed soft 
diets, although reported ongoing diet restrictions at 12 months post-treatment [12, 15-17]. A number of 
reports describe “swallowing solids” [31] or “more or less normal oral feeding” [32] as positive 
outcomes for the CRT population without quantifying their function in more detail. Less information is 
known about the AFRT population diet tolerance post-treatment with initial data suggesting mild 
difficulty swallowing solids post-treatment [6]. 
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Despite the statistical difference in diet consistency managed, group comparisons found no significant 
difference between the physiological impairments observed in both participant groups. Irrespective of 
treatment received, more than half the participants developed mild or mild-moderate physiological 
impairment in swallowing function, specifically in mastication, pharyngeal contraction/bolus 
propulsion, laryngeal excursion, bolus propulsion through the UES and clearance of pyriform sinus 
residue at 6 months post-treatment. This may suggest a comparable physiological outcome, or may be 
due to small numbers studied. The fact that both cohorts presented with similar physiological swallow 
impairments could potentially be attributed similar physiological structures included in the treatment 
field required for curative intent radiotherapy for oropharyngeal SCC, regardless of the treatment 
intensification modality (AFRT-CB or CRT) used [5, 16].  
 
The reasoning behind why the two groups presented with significantly different diet restrictions and yet 
were not different on physiological assessment may be attributable to the large variance associated with 
small participant numbers. However, restrictions in oral intake have been previously associated with 
videofluoroscopic measures of reduced laryngeal excursion, reduced cricopharyngeal opening, and 
evidence of aspiration and/or residue [33]. In the current study, descriptive analysis revealed that the 
pharyngeal and crico-esophageal phases were impaired with slightly higher frequency in the CRT 
group, which may have resulted in greater texture restriction, perceived need for supplemental feeding 
and overall inferior functional swallowing. However, it is also possible that the lack of agreement 
between the clinical and physiological swallowing findings may be due to other factors such as 
ongoing xerostomia, pain or fatigue further limiting oral intake for the CRT participants. In the absence 
of any systematic investigation of these aspects in the current study, further research is needed to 
determine the influence of such factors on texture limitations in a large cohort.   
 
Although statistical comparison between the two groups failed to identify any significant differences in 
physiological swallowing characteristics, descriptive analysis did reveal some patterns which were 
more distinctive in each group. In the CRT group there were statistical trends observed for more 
deficits in lingual control and increased aspiration risk on thin fluids, possibly due to the potential 
sequelae of the addition of chemotherapy to conventional radiotherapy. Late effects of CRT treatment 
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have been reported to include chronic fibrosis resulting in stiffening of the tongue and hyolaryngeal 
complex [14], reduced glottic closure and oesophageal stenosis [34], that leads to significant 
oropharyngeal residue and aspiration. Indeed, a systematic review by van der Molen [35] found that 
chemoradiation regimens were associated with an increased aspiration rate, and this may result from 
the toxic effect on the neuromuscular junctions causing generalised weakness, fatigue, and sensory 
changes [36]. 
 
Specific to AFRT-CB, physiological assessment revealed that aspects of oral and oropharyngeal 
dysfunction were slightly more severe and frequent, although mild in nature, compared to the CRT 
group. This may be subsequent to the severe acute injury associated with altered fractionation protocols 
[8, 9], including delayed healing of mucosa, early onset of late tissue injury (soft tissue or bone 
necrosis), and chronic oedema [3]. These effects may result in ongoing oral ulceration and pain, 
trismus, and xerostomia that may affect the oral and oropharyngeal transit parameters of swallowing 
including palatal closure, mastication, and relative timing of the onset of swallow, as found in the 
current study.  
 
With respect to patient perceptions, functional impact at 6 months post-treatment was found to be 
similarly impaired between the two treatment groups, with both experiencing less than optimal function 
in the head and neck specific concerns and overall function assessed by the FACT-H&N, and in all 
domains of the MDADI. Comparisons with studies of CRT populations at 6 months revealed that the 
current data is similar, with ongoing patient-reported deficits in xerostomia, mastication, swallowing, 
taste and pain noted to have improved. This may indicate adjustment to ongoing impairment [17, 31]. 
While there are limited reports of patient-rated function following AFRT, the FACT-H&N scores 
reported by the current groups of participants are comparable to those reported by Ringash, et al. [37] 
for a cohort of 171 heterogenous patients treated with accelerated AFRT at 6 months. 
 
Considering that only 43% of the AFRT-CB group and 18% of the CRT group could manage a normal 
diet, it is not surprising that most patients perceived they had less than optimal self-rated swallowing 
function. Although it may be argued that a soft diet is “near-normal” and is a good outcome, it is 
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important to note that the majority of participants in the current cohort, independent of treatment, were 
consuming soft diets and reported reduced functioning across the global, emotional, functional and 
physical domains on the MDADI. This supports that even when able to resume “near-normal” oral 
intake consistencies, patients continue to regard their function as far less than normal. This relationship 
between slight texture modification and reduced patient perception of function has been noted 
previously by other researchers [38, 39], and highlights that even small limitations to oral intake 
variety may translate as negative outcomes for patients. Clinicians need to be sensitive to this as they 
support patients through recovery and rehabilitation.  
 
Nutritional outcomes following both AFRT-CB and CRT did not differ significantly at 6 months post-
treatment, with both groups losing close to 10kg. However, there was an indication for poorer 
outcomes in the CRT group with ongoing requirements for supplemental tube feeding in a small 
number of participants. The current study found 12% of CRT patients required gastrostomy tube 
feeding at 6 months post-treatment, a similar rate to that found previously [16], but less than the 38-
64% requiring supplemental PEG feeding at 5-6 months post-treatment in other studies [12, 15]. These 
reports of higher alternative feeding rates were related to higher rates of aspiration (64-78%) and 
therefore greater recommendations to utilise alternative feeding. Participants who received AFRT-CB 
in the current study did not require alternative feeding at 6 months which is in agreement with previous 
studies [6].  
 
While this is the first study to elucidate whether functional outcomes (swallowing, nutrition and 
patient-rated functional impact) following non-surgical treatment for oropharyngeal cancer differ 
between CRT and AFRT, the limitations of this study are recognized. Small accrual has not allowed for 
detailed inferential analysis, and therefore the results discussed here cannot be generalized across this 
population. Further limitations include the absence of objective baseline and longitudinal data, and 
treatment selection causing age differences in groups. Increasing age has been associated with 
dysphagia in normal elderly populations [40], and may have contributed negatively to functional 
outcomes in the AFRT-CB population. However, age has been found to be an important factor in 
determining tolerance of treatment in the HNC population, with lower compliance and higher toxicity 
rates in older patients receiving CRT [10]. In this way, the feasibility of comparing age-matched 
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groups across these two treatment types may continue to prove difficult.  Treatment selection also 
caused staging variability across groups (although not statistically different), another factor which may 
have confounded results. 
 
CONCLUSIONS 
The current preliminary study found inferior outcomes in functional swallowing for CRT patients 
compared with AFRT-CB patients and was reflected by increased food/fluid restriction, and greater 
requirements for supplemental feeding at 6 months post-treatment. Differences in functional 
swallowing did not translate into significant differences in swallowing physiology, nutrition or patient-
rated functional impact. This lack of significant findings may have resulted from small participant 
numbers, or may suggest that patients who receive AFRT are largely comparable to those who receive 
CRT, experience similar mild-moderate physiological swallowing impairment that impacts on nutrition 
and patient-rated function in an equivalent manner. Although further research is required to elucidate 
these findings, there may be some suggestion that equal service provision should be provided to both 
populations rather than resources being biased toward CRT groups. Future investigations require a 
multicentred approach to ensure a large cohort of participants. It is hoped that the current study may 
inform the development of appropriately powered studies to prospectively examine the functional 
outcomes following intensified non-surgical treatment modalities in patients with oropharyngeal 
cancer. 
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Table 1. Demographic comparisons between AFRT-CB and CRT groups 
 
Demographic 
 AFRT-CB 
M (SD) or 
n (%) 
CRT 
M (SD) or 
n (%) 
Statistic 
Z / χ2 
 
p 
Age (years) 
 
 66.6 (8.7) 
range = 53-82 
54.9 (10.9) 
range = 34-69 
 
Z = 2.81 0.005 
Weighta (kgs) 
 
 83 (18.9) 80 (22.7) t = -0.34 0.36 
Sex Male 
Female 
 
12 (86) 
2 (14) 
15 (88) 
2 (12) 
χ2 = 0.18 0.67 
Site Tonsil 
BOT 
Supraglottis 
Pharyngeal wall 
 
 9 (64) 
1 (7) 
3 (21) 
1 (7) 
10 (59) 
 3 (18) 
 2 (12) 
2 (12) 
χ2 = 16.72 0.053 
Size T1 
T2 
T3 
 
4 (29) 
7 (50) 
3 (21) 
4 (24) 
7 (41) 
6 (35) 
χ2 = 0.67 0.96 
Nodal N0 
N1 
N2a 
N2b 
N2c 
N3 
 
9 (64) 
2 (14) 
2 (14) 
1 (7) 
1 (6) 
3 (18) 
2 (12) 
6 (41) 
1 (6) 
2 (18) 
χ2 = 16.72 0.34 
Stage I 
II 
III 
IV 
 
2 (14) 
4 (29) 
5 (36) 
3  (21) 
0 
0 
4 (24) 
13 (76) 
χ2 = 2.91 0.41 
Smoking Current 
Ex 
Never 
 
3 (21) 
7 (50) 
4 (29) 
6 (35) 
9 (53) 
2 (12) 
χ2 = 6.99 0.14 
Alcoholb Current  
Ex 
Never 
 
12 (86) 
2 (14) 
15 (88) 
1 (6) 
1 (6) 
χ2 = 0.09 0.76 
Dysphagia for 
liquids 
 
Yes 
No 
0 
14 (100) 
0 
17 (100) 
-  - 
Dysphagia for 
solids 
 
Yes 
No 
3 (21) 
11 (79) 
6 (35) 
11 (65) 
χ2 = 0.72 0.4 
a Pre-treatment weight 
b No information re: alcohol intake available for one AFRT-CB participant
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Table 2. Diet and fluid consistencies reported at 6 months post-treatment 
 
 Consistency AFRT-CB 
n (%) 
CRT 
n (%) 
Fluids Thin 14 (100) 14 (82) 
 Mildly thick 0 3 (18) 
    
Solids Full 6 (43) 3 (18) 
 Soft 8 (57) 11 (65) 
 Minced 0 2 (12) 
 Pureed 0 1 (6) 
    
Supplemental tube feeding*  0 2 (12) 
*Supplemental tube feeding required with some oral intake
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Table 3. Severity of swallowing impairment at 6 months post-treatment 
 
 Parameter Component AFRT-CB 
N = 14 
M (SD) 
CRT 
N = 17 
M (SD) 
 
 
Z 
 
 
p 
NZIMESa Oral Labial closure - - 0 0 
  Lingual control 0.07 (0.27) 0.35 (0.49) 1.84 0.07 
  Palatal closure 0.57 (0.65) 0.35 (0.49) -0.94 0.35 
  Mastication 
 
1.5 (0.65) 1.12 (0.6) -1.52 0.13 
 Oral Pharyngeal 
Transit 
Position of bolus at onset 
of swallow 
0.71 (0.91) 0.65 (0.79) -0.09 0.93 
  Relative timing of onset 
of swallow 
 
0.43 (0.51) 0.24 (0.44) -1.13 0.26 
 Pharyngeal Velopharyngeal closure 0 (0) 0.18 (0.53) 1.31 0.19 
  Pharyngeal contraction + 
bolus propulsion 
1 (0.56) 1 (0.87) 0.00 1.0 
  Laryngeal excursion 
 
0.5 (0.52) 0.88 (0.78) 1.37 0.17 
 Crico-esophageal Bolus propulsion through 
UES 
0.57 (0.65) 0.77 (0.75) 0.7 0.49 
  Clearance of pyriform 
sinus residue 
0.57 (0.65) 0.88 (0.93) 0.86 0.39 
  Upper esophageal 
parameters 
 
- - 0 0 
Penetration-
Aspiration 
Scaleb 
 Fluids 2.21 (1.85) 3 (1.9) 1.8 0.07 
  Solids 
 
2.79 (1.76) 3.59 (2.81) 3.89 0.7 
a New Zealand Index for Multidisciplinary Examination of Swallowing: severity ratings for each 
component from 0 (no significant impairment) to 4 (profound impairment) 
b Penetration-Aspiration Scale: severity ratings from 1 (material does not enter the airway) to 8 
(material enters the airway, passes below the vocal folds, and no effort is made to eject) 
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Table 4.  Frequency of swallowing impairment at 6 months*  
 
NZIMES Parameter Component 
 
n (%) rated with 
“impairment” 
 
 AFRT CRT 
Oral Labial Closure 0 0 
 Lingual Control 2 (7) 6 (35) 
 Palatal Closure 7 (50) 6 (35) 
 Mastication 
 
14 (100) 15 (88) 
 
Oral Pharyngeal Position of bolus at onset of swallow 6 (43) 8 (47) 
 Relative timing of onset of swallow 
 
6 (43) 4 (24) 
 
Pharyngeal Velopharyngeal Closure 0 2 (12) 
 Pharyngeal Contraction/Bolus Propulsion 12 (86) 11 (65) 
 Larygneal Excursion 
 
7 (50) 11 (65) 
 
Crico-esophageal Bolus Propulsion through UES 7 (50) 10 (59) 
 Clearance of Pyriform Sinus Residual 7 (50) 10 (59) 
 Upper Esophageal Parameters 
 
0 0 
 
*NZIMES data compressed into binary scale of “no impairment” vs “impairment”
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Table 5. Frequency of penetration and aspiration events 
Penetration-Aspiration 
Scale 
6 months post-treatment 
n (%)  
 AFRT-CB CRT 
Fluids 12 (86) 9 (53) Nil 
 
Solids 8 (57) 8 (47) 
Fluids 1 (7) 6 (35) Penetration 
 
Solids 4 (29) 2 (12) 
Fluids 1 (7) 2 (12) Aspiration 
 
Solids 2 (14) 7 (41) 
  
 
- 25 - 
 Table 6. Patient-rated functional impact outcomes at 6 months post-treatment 
 
 
Tool 
 
Domain (range) 
AFRT-CB  
N = 14 
M (SD) 
CRT 
N = 17 
M (SD) 
 
 
Z 
 
 
p 
FACT- H&Na Emotional (0-24) 21 (2.5) 18.5 (4.3) -1.59 0.11 
 Functional (0-28) 19.1 (6.9) 17.9 (6.4) -0.78 0.44 
 Physical (0-28) 21.5 (6.1) 18.9 (7.0) -1.22 0.22 
 Social/Family (0-28) 21 (7.4) 19.9 (6.2) -0.74 0.46 
 Head and Neck Specific (0-44) 30.1 (6.6) 28.5 (7.7) -0.56 0.58 
 Overall (0-152) 115.6 (22.7) 103.6 (24.9) -1.31 0.19 
      
MDADIb Global (0-100) 68.6 (21.8) 62.4 (28.2) -0.48 0.63 
 Emotional (0-100) 76.2 (17.6) 68.8 (19.7) -1.08 0.28 
 Functional (0-100) 77.4 (13.9) 68 (23.8) -1.04 0.3 
 Physical (0-100) 
 
69.3 (12.1) 60.3 (21.6) -1.67 0.1 
a Functional Assessment of Cancer Therapy Additional Concerns for Head and Neck version 4 
b M. D. Anderson Dysphagia Inventory 
 
 
 
 
 
 
 
 
 
 
 
 
